Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs

Diabetes Research and Clinical Practice

Volumn 88, Issue 3, 2010, Pages 282-288

  Kalra, Sanjay ^a   Plata Que, Teresa ^b   Kumar, Dileep ^c   Mumtaz, Malik ^d   Søndergaard, Flemming ^e   Kozlovski, Plamen ^e   Bebakar, Wan Mohamad Wan ^f  

^a Wazir Chand Colony ^*  (India)

^b East Avenue Medical Center ^*  (Philippines)

^c ANDHRA MEDICAL COLLEGE   (India)

^d PENANG MEDICAL COLLEGE   (Malaysia)

^e NOVO NORDISK A S   (Denmark)

^f HOSPITAL UNIVERSITI SAINS MALAYSIA   (Malaysia)

Author keywords

Asian patients with type 2 diabetes; Biphasic insulin aspart 30; Insulin glargine; Insulin initiation

Indexed keywords

BIASP 30; FLEXPEN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; NOVOMIX30; OPTISET; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN;

ADULT; ARTICLE; ASIAN; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES CONTROL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; WEIGHT GAIN; ADOLESCENT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG DOSAGE FORM; HYPOGLYCEMIA; INTERNATIONAL COOPERATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INTERNATIONAL AGENCIES; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78349300259     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.03.004     Document Type: Article

References (35)

1. World Health Organization, Preventing chronic diseases: a vital investment, WHO Global Report, 2006. http://www.who.int/chp/chronic_disease_report/en/.
2. International Diabetes Federation Diabetes Atlas 2003, International Diabetes Federation, Brussels, Belgium. second ed.
3. Wright A., Burden A.C., Paisey R.B., Cull C.A., Holman R.R. U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diab. Care 2002, 25(2):330-336.
4. American Association of clinical Endocrinologists Medical guidelines for the management of diabetes mellitus. Endocr. Pract. 2003, 8:40-65.
5. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
6. Asian-Pacific Type 2 Diabetes Policy Group, Type 2 Diabetes. Practical Targets and Treatments. fourth ed., 2005. http://www.idf.org/webdata/docs/T2D_practical_tt.pdf.
7. Mohamed M. An audit on diabetes management in Asian patients treated by specialists: the Diabcare-Asia 1998 and 2003 studies. Curr. Med. Res. Opin. 2008, 24(2):507-514. Diabcare-Asia 2003 Study Group.
8. Pan C.Y., So W.Y., Khalid B.A., Mohan V., Thai A.C., Zimmet P., et al. Metabolic, immunological and clinical characteristics in newly diagnosed Asian diabetes patients aged 12-40 years. Diab. Med. 2004, 21(9):1007-1013.
9. Alvarsson M., Sundkvist G., Lager I., Henricsson M., Berntorp K., Fernqvist-Forbes E., et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diab. Care 2003, 26(8):2231-2237.
10. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diab. Care 2001, 24(4):758-767.
11. Riddle M. Timely addition of insulin to oral therapy for type 2 diabetes. Diab. Care 2002, 25(2):395-396.
12. Yki-Jarvinen H., Dressler A., Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diab. Care 2000, 23(8):1130-1136. HOE 901/300s Study Group.
13. Riddle M., Rosenstock J., Gerich J. Insulin Glargine 4002 Study investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diab. Care 2003, 26(11):3080-3086.
14. International Diabetes Federation Global Guidelines for Type 2 Diabetes 2005, International Diabetes Federation, Brussels, Belgium.
15. Malone J.K., Kerr L.F., Campaigne B.N., Holcombe J.H. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin. Ther. 2004, 26(12):2034-2044. Lispro Mixture-Glargine Study Group.
16. Malone J.K., Bai S., Reviriego J., Reviriego J., Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin. therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diab. Med. 2005, 22(4):374-381.
17. Raskin P., Allen E., Hollander P., Lewin A., Gabbay R.A., Hu P., et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diab. Care 2005, 28(2):260-265.
18. Christiansen J.S., Vaz J.A., Metelko Z., Bogoev M., Dedov I. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diab. Obes. Metab. 2003, 5(6):446-454.
19. Jacobsen L.V., Sogaard B., Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur. J. Clin. Pharmacol. 2000, 56(5):399-403.
20. Garber A.J. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006, 66(1):31-49.
21. Garber A.J., Wahlen J., Wahl T., Bressler P., Braceras R., Allen E., et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diab. Obes. Metab. 2006, 8(1):58-66.
22. Strojek K., Bebakar W.M., Khutsoane D.T., Pesic M., Smahelová A., Thomsen H.F., et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr. Med. Res. Opin. 2009, 25(12):2887-2894.
23. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000, 284:3043-3045.
24. International Conference on Harmonisation: ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1), 1996. http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf.
25. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diab. Care 2006, 29(8):1963-1972.
26. Fritsche A., Schweitzer M., Haring H.-U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann. Int. Med. 2003, 138(12):952-959. 4001 St udy Group.
27. Kann P.H., Wascher T., Zackova V., Moeller J., Medding J., Szocs A., et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp. Clin. Endocrinol. Diab. 2006, 114:527-532.
28. Pan C.Y., Sinnassamy P., Chung K.D., Kim K.W. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diab. Res. Clin. Pract. 2007, 76(1):111-118. LEAD Study Investigators Group.
29. Almustafa M., Yeo J.P., Khutsoane D. Glycaemic control and hypoglycaemia in the PRESENT study. Diab. Res. Clin. Pract. 2008, 81(Suppl. 1):S10-S15.
30. Cryer P.E., Davis S.N., Shamoon H. Hypoglycemia in diabetes. Diab. Care 2003, 26(6):1902-1912.
31. Korytowski M. When oral agents fail: practical barriers to starting insulin. Int. J. Obes. Relat. Metab. Disord. 2002, 26(Suppl. 3):S18-S24.
32. 1c. Diab. Care 2003, 26(3):881-885.
33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853. The U.K. Prospective Diabetes Study (UKPDS) Group.
34. Raz I., Weinstein J., Hershkovitz T.A., Menuchin O., Abraham Z., Lindholm A. Add-on of insulin or a second oral agent? Evaluation of premixed insulin aspart in combination with repaglinide, glibenclamide, metformin and rosiglitazone [abstract]. Diabetologia 2002, 45(Suppl. 2):A263.
35. Kvapil M., Mikolajczyk-Swatko A., Ostergaard A.H., Shestakova M. In patients with poorly controlled Type 2 diabetes, biphasic insulin aspart 30 combined with metformin provides better glycaemic control than sulphonylurea/metformin combination [abstract]. Diabetologia 2002, 45(Suppl. 2):A18.